dc.contributor.author | Tomini, F | |
dc.contributor.author | Prinzen, F | |
dc.contributor.author | van Asselt, ADI | |
dc.date.accessioned | 2019-03-07T12:47:30Z | |
dc.date.available | 2015-11-25 | |
dc.date.available | 2019-03-07T12:47:30Z | |
dc.date.issued | 2016-01-04 | |
dc.identifier.citation | Tomini, F., et al. (2016). "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure." The European Journal of Health Economics 17(9): 1159-1172. | en_US |
dc.identifier.issn | 1618-7598 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/55911 | |
dc.description.abstract | Objectives
Cardiac resynchronization therapy with a biventricular pacemaker (CRT-P) is an effective treatment for dyssynchronous heart failure (DHF). Adding an implantable cardioverter defibrillator (CRT-D) may further reduce the risk of sudden cardiac death (SCD). However, if the majority of patients do not require shock therapy, the cost-effectiveness ratio of CRT-D compared to CRT-P may be high. The objective of this study was to systematically review decision models evaluating the cost-effectiveness of CRT-D for patients with DHF, compare the structure and inputs of these models and identify the main factors influencing the ICERs for CRT-D.
Methods
A comprehensive search strategy of Medline (Ovid), Embase (Ovid) and EconLit identified eight cost-effectiveness models evaluating CRT-D against optimal pharmacological therapy (OPT) and/or CRT-P.
Results
The selected economic studies differed in terms of model structure, treatment path, time horizons, and sources of efficacy data. CRT-D was found cost-effective when compared to OPT but its cost-effectiveness became questionable when compared to CRT-P.
Conclusions
Cost-effectiveness of CRT-D may increase depending on improvement of all-cause mortality rates and HF mortality rates in patients who receive CRT-D, costs of the device, and battery life. In particular, future studies need to investigate longer-term mortality rates and identify CRT-P patients that will gain the most, in terms of life expectancy, from being treated with a CRT-D. | en_US |
dc.description.sponsorship | This work was supported by the Center for Translational Molecular Medicine and The Netherlands Heart Foundation under the ‘Biomarkers to predict cardiac failure, arrhythmias and success of treatment’ (COHFAR) project | en_US |
dc.format.extent | 1159 - 1172 | |
dc.language.iso | en | en_US |
dc.publisher | SpringerLink | en_US |
dc.relation.ispartof | EUROPEAN JOURNAL OF HEALTH ECONOMICS | |
dc.rights | Creative Commons Attribution | |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | Review | en_US |
dc.subject | Cost-effectiveness | en_US |
dc.subject | Cardiac resynchronization therapy | en_US |
dc.subject | Cardiac pacing | en_US |
dc.subject | Implantable cardioverter-defibrillator | en_US |
dc.subject | Markov chains | en_US |
dc.subject | Models | en_US |
dc.subject | Economic | en_US |
dc.subject | Heart failure | en_US |
dc.subject | Sudden cardiac death | en_US |
dc.title | A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure | en_US |
dc.type | Article | en_US |
dc.rights.holder | The Author(s) 2016 | |
dc.identifier.doi | 10.1007/s10198-015-0752-3 | |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000392436000009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 9 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 17 | en_US |
dcterms.dateAccepted | 2015-11-25 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |